Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

NCT02215265 is registered in ClinicalTrials.gov with Lisette Nixon as lead sponsor.

NCT NCT02215265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02215265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Lead sponsor
Lisette Nixon
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 31, 2015
Completion date
April 30, 2028
Enrollment
1,269 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus (hpv)-positive oropharyngeal cancer